Acebutolol (Monograph)
Brand name: Sectral
Drug class: alpha-Adrenergic Blocking Agents
Introduction
A short-acting β1-selective adrenergic blocking agent (β-blocker).1 2 17 18 113
Uses for Acebutolol
Hypertension
Management of hypertension (alone or in combination with other classes of antihypertensive agents).1 280 1200
β-Blockers generally not preferred for first-line therapy of hypertension according to current evidence-based hypertension guidelines, but may be considered in patients who have a compelling indication (e.g., prior MI, ischemic heart disease, heart failure) for their use or as add-on therapy in those who do not respond adequately to the preferred drug classes (ACE inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, or thiazide diuretics).361 501 502 503 504 515 523 524 527 800 1200 A 2017 ACC/AHA multidisciplinary hypertension guideline states that β-blockers used for ischemic heart disease that are also effective in lowering BP include bisoprolol, carvedilol, metoprolol succinate, metoprolol tartrate, nadolol, propranolol, and timolol.1200
Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).501 502 503 504 515 1200 1201
The 2017 ACC/AHA hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension.1200 (See Table 1.)
Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.
Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).
Category |
SBP (mm Hg) |
DBP (mm Hg) |
|
---|---|---|---|
Normal |
<120 |
and |
<80 |
Elevated |
120–129 |
and |
<80 |
Hypertension, Stage 1 |
130–139 |
or |
80–89 |
Hypertension, Stage 2 |
≥140 |
or |
≥90 |
The goal of hypertension management and prevention is to achieve and maintain optimal control of BP.1200 However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.501 503 504 505 506 507 508 515 523 526 530 1200 1201 1207 1209 1222 1223 1229
The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) of <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.1200 In addition, an SBP goal of <130 mm Hg generally is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg.1200 These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.1200 1202 1210
Other hypertension guidelines generally have based target BP goals on age and comorbidities.501 504 536 Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk and have used higher BP thresholds and target BPs in elderly patients501 504 compared with those recommended by the 2017 ACC/AHA hypertension guideline.1200
Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the 2017 ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.1222 1223 1224 1229
Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient's BP treatment goal.1200 1220 1229
For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors.1200 1207 ASCVD risk assessment is recommended by ACC/AHA for all adults with hypertension.1200
ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).1200
For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.1200
Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.1200 Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.502 1200
In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP.1200 Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.1200
Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to β-blockers.355 359 360 501 504 1200 However, diminished response to β-blockers is largely eliminated when administered concomitantly with a thiazide diuretic.500
Cardiac Arrhythmias
Treatment of frequent ventricular premature complexes (VPCs), including uniform and multiform VPCs and/or coupled VPCs, and R-on-T complexes1 2 137 185 186 187 188 189 190 193 194 195 196 197 198 199 201 204 in patients with primary arrhythmias or arrhythmias secondary to various cardiac disorders (e.g., CAD,137 185 186 187 188 189 194 acute MI,137 186 187 193 194 195 196 valvular disease).185 186 187 189 190
Management of various supraventricular tachyarrhythmias† [off-label].191 192 196 200 202 203 256 266
Angina
Management of chronic stable angina pectoris† [off-label].205 206 207 208 209 210 211 212 213 214 220 221 222 223 224 225
Acute MI
Secondary prevention following acute MI† [off-label] to reduce the risk of reinfarction and mortality.289 290
Related/similar drugs
amlodipine, lisinopril, metoprolol, losartan, furosemide, hydrochlorothiazide, sotalol
Acebutolol Dosage and Administration
General
-
β-Adrenergic blocking selectivity diminishes as dosage is increased.1
-
If long-term therapy is discontinued, reduce dosage gradually over a period of about 2 weeks.1 2 (See Abrupt Withdrawal of Therapy under Cautions.)
-
When substituting another β-blocker for acebutolol, initiate at a comparable dosage without interruption of β-blocker therapy.1 2
BP Monitoring and Treatment Goals
-
Monitor BP regularly (i.e., monthly) during therapy and adjust dosage of the antihypertensive drug until BP controlled.1200
-
If unacceptable adverse effects occur, discontinue drug and initiate another antihypertensive agent from a different pharmacologic class.1216
-
If adequate BP response not achieved with a single antihypertensive agent, either increase dosage of single drug or add a second drug with demonstrated benefit and preferably a complementary mechanism of action (e.g., ACE inhibitor, angiotensin II receptor antagonist, calcium-channel blocker, thiazide diuretic).1200 1216 Many patients will require ≥2 drugs from different pharmacologic classes to achieve BP goal; if goal BP still not achieved, add a third drug.1200 1216
Administration
Acebutolol hydrochloride is administered orally.1 2 Also been administered IV† [off-label],25 27 28 29 41 191 192 196 200 202 203 266 but a parenteral dosage form is currently not commercially available in the US.
Oral Administration
Hypertension
Usually administer as a single daily dose;1 245 however, for 24-hour BP control, some patients may require administration of the daily dose in 2 divided doses.1 142 143 144 145 149 155
Ventricular Arrhythmias
Twice-daily dosing of the drug appears to be more effective than once-daily dosing for the suppression and prevention of frequent VPCs.4 185 186 188 189 195 198 199 203 204 248
Angina
Once-daily administration may be as effective as divided doses;4 208 249 however, further studies are needed.4
Dosage
Available as acebutolol hydrochloride; dosage expressed in terms of acebutolol.1
Adults
Hypertension
Oral
Initially, 200–400 mg daily.1 245 321 Manufacturer and some clinicians state usual maintenance dosage is 400–800 mg daily, 1 140 142 143 144 145 149 150 151 152 153 154 245 246 247 but some patients may achieve adequate BP control with dosages as low as 200 mg daily.1 4
Increase dosage up to 1.2 g daily in 2 divided doses in patients with more severe hypertension or if adequate reduction of BP does not occur;1 2 4 140 142 143 144 145 149 150 151 152 154 155 alternatively, add another hypotensive agent (e.g., thiazide diuretic).1 2 4 142 144 157 158 160 161 165 166 168
Some experts state usual dosage range is 200–800 mg daily, administered in 2 divided doses.1200
Ventricular Arrhythmias
Oral
Initially, 200 mg twice daily.1 187 196 Increase gradually until optimum effect is achieved.1 185 186 195 198 204 Usual maintenance dosage is 600–1200 mg daily.1 2 4 185 186 189 190 195 199 204
Angina
Oral
Initially, 200 mg twice daily.4 205 208 Increase dosage gradually until optimum effect is achieved.4 205 Usual maintenance dosage is 800 mg or less daily,4 206 207 208 209 210 211 212 213 214 but patients with severe angina may require higher dosages.4 205 209 211
Adjust dosage of β-blockers according to clinical response4 205 and to maintain a resting heart rate of 55–60 bpm.211 216
Prescribing Limits
Adults
Hypertension
Oral
Maximum 1.2 g daily.1 2 4 140 142 143 144 145 149 150 151 152 154 155
Special Populations
Renal Impairment
Active metabolite (diacetolol) eliminated principally by the kidneys;1 123 125 dosage and/or frequency of administration must be modified in response to the degree of renal impairment.1 2 86 123 124 125 126 127
Reduction in Usual Daily Dosage |
Clcr (mL/min) |
---|---|
50% |
25–49 mL/minute |
75% |
<25 mL/minute |
Acebutolol and diacetolol removed by hemodialysis;1 125 127 individualize dosage carefully in patients with severe renal impairment who undergo chronic intermittent hemodialysis.124 125
Geriatric Patients
Consider reduction in maintenance dosage.1 2 Avoid dosages >800 mg daily.1 2
Cautions for Acebutolol
Contraindications
-
Patients with heart block greater than first degree, severe bradycardia, cardiogenic shock, or overt cardiac failure.1
Warnings/Precautions
Warnings
Heart Failure
Possible precipitation of heart failure.1
Avoid use in patients with decompensated heart failure; use cautiously in patients with inadequate myocardial function and, if necessary, in patients with well-compensated heart failure (e.g., those controlled with cardiac glycosides and/or diuretics).1
Adequate treatment (e.g., with a cardiac glycoside and/or diuretic) and close observation recommended if signs or symptoms of impending cardiac failure occur; if cardiac failure continues, discontinue therapy, gradually if possible.1
Abrupt Withdrawal of Therapy
Possible exacerbated angina symptoms or precipitation of MI in patients with CAD.1 Abrupt discontinuance of therapy is not recommended.1 276 Gradually decrease dosage over a period of about 2 weeks; monitor patients carefully and advise to temporarily limit their physical activity.1 276 If exacerbation of angina occurs, reinstitute therapy promptly and initiate appropriate measures for the management of unstable angina pectoris.1
Peripheral Vascular Disease
Possible reduction in cardiac output and precipitation or aggravation of symptoms of arterial insufficiency.1 Use with caution; observe for evidence of disease progression.1
Bronchospastic Disease
Possible bronchoconstriction.1
Use with caution in patients with bronchospastic disease; administer the lowest effective dosage (initially in divided doses). A bronchodilator (e.g., a β2-adrenergic agonist, theophylline) should be available for immediate use, if necessary.1
Major Surgery
Possible risks associated with general anesthesia (e.g., severe hypotension, maintenance of heart beat) due to decreased ability of the heart to respond to reflex β-adrenergic stimuli.1 Use with caution in patients undergoing major surgery involving general anesthesia; anesthetics used should not cause myocardial depression.1
Diabetes and Hypoglycemia
Possible decreased signs and symptoms of hypoglycemia (e.g., tachycardia, palpitation, BP changes, tremor, feelings of anxiety, but not sweating or dizziness) and increased insulin-induced hypoglycemia.1
Use with caution in patients with diabetes mellitus.1
Thyrotoxicosis
Signs of hyperthyroidism (e.g., tachycardia) may be masked.1 Possible thyroid storm if therapy is abruptly withdrawn; carefully monitor patients having or suspected of developing thyrotoxicosis.1
Sensitivity Reactions
Anaphylactic Reactions
Patients with a history of anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenges with such allergens while taking β-blocking agents.1 Such patients may be unresponsive to usual doses of epinephrine.1
Specific Populations
Pregnancy
Category B.1
Lactation
Distributed into milk in higher concentrations than in maternal plasma.1 2 105 Use not recommended by manufacturer.1
Pediatric Use
Safety and efficacy not established in children <12 years of age.1 268
Geriatric Use
Insufficient experience in patients >65 years of age to determine whether geriatric patients respond differently than younger adults.1 However, reduction of maintenance dosage may be necessary,1 2 since bioavailability of acebutolol and diacetolol (active metabolite) may be increased compared with that in younger adults.1 2 122 (See Geriatric Patients under Dosage and Administration.)
Hepatic Impairment
Use with caution.1 2 Cirrhosis does not appear to substantially affect the pharmacokinetics of acebutolol or diacetolol; however, the effects of hepatic impairment on elimination of the drug have not been fully evaluated.128
Renal Impairment
Use with caution; dosage should be reduced based on the degree of renal impairment.1 (See Renal Impairment under Dosage and Administration.)
Common Adverse Effects
Fatigue, dizziness, headache, dyspnea, constipation, diarrhea, dyspepsia, nausea, flatulence, insomnia, increased micturition, chest pain, edema, depression, abnormal dreams, rash, arthralgia, myalgia, cough, rhinitis, abnormal vision.1
Drug Interactions
Specific Drugs
Drug |
Interaction |
Comments |
---|---|---|
α-Adrenergic agonists1 |
Possible exaggerated hypertensive reactions1 |
Warn patients of potential hazard1 |
Calcium-channel blockers |
Potential additive depressant effects on SA or AV nodal conduction318 319 |
|
Cardiac glycosides (digoxin) |
Potential additive depressant effects on SA or AV nodal conduction318 319 Pharmacokinetic interaction unlikely1 |
|
Diuretics |
Possible increased hypotensive effect1 2 142 144 157 158 160 |
|
Glyburide |
Possible decreased hypoglycemic action in type II diabetic patients, presumably by decreasing insulin secretion244 |
|
Hydralazine |
Pharmacokinetic interaction unlikely1 |
|
Hydrochlorothiazide |
Pharmacokinetic interaction unlikely1 |
|
Hypotensive agents |
Possible increased hypotensive effect1 2 142 144 157 158 160 |
|
NSAIAs |
Potential blunting of hypotensive effects1 |
|
Oral contraceptives |
Pharmacokinetic interaction unlikely1 |
|
Reserpine |
Possible additive pharmacologic effects1 |
Observe closely for evidence of marked bradycardia or hypotension (e.g., vertigo, presyncope or syncope, or orthostatic changes in BP without compensatory tachycardia)1 |
Sulfinpyrazone |
Pharmacokinetic interaction unlikely1 |
|
Sympathomimetic agents |
Antagonism of β1-adrenergic stimulating effects (e.g., bronchodilation)1 2 57 58 59 62 |
Increased dosage of β-adrenergic agonist bronchodilators may be required 268 277 |
Tolbutamide |
Interaction unlikely1 |
|
Warfarin |
Interaction unlikely1 |
Acebutolol Pharmacokinetics
Absorption
Bioavailability
Well absorbed from the GI tract following oral administration;1 2 4 11 91 109 undergoes extensive first-pass metabolism in the liver.1 2 97 99 109 122 124
Peak plasma acebutolol and diacetolol concentrations occur within 2–2.5 hours (range: 1–4 hours) and 4 hours (range: 2.4–5 hours), respectively, in healthy individuals1 2 94 95 97 98 99 126 135 or patients with hypertension91 or arrhythmias.2 90 137
Absolute bioavailability is approximately 35–50%.1 4 94 97 102
Food
Food may slightly decrease the rate of absorption and peak plasma concentrations of acebutolol and its major metabolite (diacetolol), but the extent of absorption is not substantially affected.1 2 101
Onset
Effect on resting, reflex, or exercise-induced heart rate and systolic BP begins within 1–1.5 hours,1 3 21 91 100 in healthy1 21 98 100 or hypertensive91 individuals.
Duration
Effect may persist for up to 24 hours or longer.1 3 91 98 100
Special Populations
In geriatric patients, peak plasma concentrations and AUCs of acebutolol and diacetolol are increased twofold compared with those observed in younger patients.1 2 122
Distribution
Extent
Acebutolol and diacetolol readily cross the placenta1 2 105 106 107 and can accumulate in the fetus.105 106 107
Acebutolol and diacetolol are distributed into milk at concentrations higher than those in maternal plasma. (See Lactation under Cautions.)1 2 105 106
Plasma Protein Binding
Approximately 11–25% (acebutolol) and 6–9% (diacetolol).2 93 103 Approximately 50% bound to erythrocytes.4 125
Elimination
Metabolism
Rapidly and extensively metabolized in the liver2 110 113 to metabolites (acetolol and diacetolol).2 4 6 99 108 109 110 113
Elimination Route
Acebutolol and its metabolites are excreted in feces and urine.1 87 92 109 111 123
Half-life
About 3 hours in the initial distribution phase (t½α) 95 and about 11 hours (range: 6–12 hours) in the terminal phase (t½β).95 125 About 7.5 (range: 7–11 hours) and 3 hours, respectively, for diacetolol and acetolol following a single oral dose.101 108 125
Special Populations
Renal impairment may reduce clearances of acebutolol and diacetolol.125 Acebutolol and diacetolol are removed by hemodialysis.1 125 127
Stability
Storage
Oral
Capsules
Tight containers1 253 at room temperature (approximately 25°C).1 2 3
Actions
-
Pharmacologic effects result from both the unchanged drug and diacetolol, 1 2 114 115 116 117 which is equipotent to acebutolol.1 2 114 115 116 117
-
Inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium.1 2 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 34 35 36 37 38 Blocks β2-adrenergic receptors within bronchial and vascular smooth muscle only at high doses.4 24 35 178
-
Decreases exercise-induced heart rate,1 2 4 11 12 13 23 24 25 27 inhibits reflex orthostatic tachycardia,1 2 4 11 12 13 23 24 and may decrease1 2 25 28 29 140 193 or leave unchanged 26 140 cardiac output at rest2 25 140 193 or during exercise.1 28 29 Decreases systolic and diastolic BP at rest1 2 13 19 23 56 57 139 and during exercise.1 2 155 160 171
-
Precise mechanism of hypotensive action has not been determined.7 22 26 34 35 139 178 May reduce BP by blocking peripheral (especially cardiac) adrenergic receptors (decreasing cardiac output), by decreasing sympathetic outflow from the CNS, and/or by suppressing renin release.7 26 34 35 140
-
Exhibits antiarrhythmic activity;1 2 137 185 186 187 188 189 190 193 194 195 196 199 204 considered a class II antiarrhythmic agent.254
-
Can produce nervous system effects,1 2 4 6 150 152 154 158 170 198 although the frequency and/or severity of such effects may be less than those observed with some other β-blockers.152 154 156 262
-
Unlike some β-blockers,147 148 does not consistently suppress plasma renin activity (PRA).26 71 139 140 141 142 143
-
May increase airway resistance and decrease ventilatory capacity,51 52 53 54 57 58 59 60 61 62 63 64 155 158 especially in patients with asthma and/or COPD or when high dosages are used.52 53 57 58 59 60 61 62 63 64 158 268
-
Does not appear to substantially affect glucose metabolism;73 75 however, the drug may potentiate insulin-induced hypoglycemia in diabetic patients receiving oral hypoglycemic agents.74 (See Interactions.)
Advice to Patients
-
Importance of taking acebutolol exactly as prescribed.1
-
Importance of not interrupting or discontinuing therapy without consulting clinician; patients should temporarily limit physical activity when discontinuing therapy.1 276
-
Importance of immediately informing clinician at the first sign or symptom of impending cardiac failure (e.g., weight gain, increased shortness of breath) or if any difficulty in breathing occurs.1
-
In patients with heart failure, importance of informing clinician of signs or symptoms of exacerbation (e.g., weight gain, difficulty in breathing).1
-
Importance of patients informing anesthesiologist or dentist that they are receiving acebutolol therapy prior to undergoing major surgery.1
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.1
-
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1
-
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Oral |
Capsules |
200 mg (of acebutolol)* |
Acebutolol Hydrochloride Capsules |
|
Sectral |
Promius |
|||
400 mg (of acebutolol)* |
Acebutolol Hydrochloride Capsules |
|||
Sectral |
Promius |
AHFS DI Essentials™. © Copyright 2024, Selected Revisions April 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
1. Wyeth-Ayerst Laboratories. Sectral (acebutolol hydrochloride) prescribing information. In: Physicians’ desk reference. 53rd ed. Montvale, NJ: Medical Economics Company Inc; 1999:3381-3.
2. Ives Laboratories Inc. Sectral product monograph. New York, NY; 1985 Mar.
3. Ives Laboratories Inc. Sectral product information form for American Hospital Formulary Service. Philadelphia, PA; 1985 Jan.
4. Singh BN, Thoden WR, Ward A. Acebutolol: a review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia. Drugs. 1985; 29:531-69. http://www.ncbi.nlm.nih.gov/pubmed/3891306?dopt=AbstractPlus
5. Cowling CGD, Leary WP. Acebutolol: a review. Curr Ther Res. 1981; 30:765-74.
6. De Bono G, Kaye CM, Roland E et al. Acebutolol: ten years of experience. Am Heart J. 1985; 109(5 Part 2):1211-24. http://www.ncbi.nlm.nih.gov/pubmed/2859785?dopt=AbstractPlus
7. Anon. Acebutolol. Med Lett Drugs Ther. 1985; 27:58-60. http://www.ncbi.nlm.nih.gov/pubmed/3892259?dopt=AbstractPlus
8. Abernethy DR, Arendt RM, Greenblatt DJ. Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration. Am Heart J. 1985; 109(5 Part 2):1120-5. http://www.ncbi.nlm.nih.gov/pubmed/2859774?dopt=AbstractPlus
9. Ryan JR. Clinical pharmacology of acebutolol. Am Heart J. 1985; 109(5 Part 2):1131-6. http://www.ncbi.nlm.nih.gov/pubmed/2859776?dopt=AbstractPlus
10. Mimnaugh MN, Gearien JE. Adrenergic drugs. In: Foye WO, ed. Principles of medicinal chemistry. 2nd ed. Philadelphia: Lea & Febiger; 1981:377-93.
11. Maxwell DR, Collins RF. Acebutolol (Sectral): I—review of the pharmacology and pharmacokinetics. Clin Trials J. 1974; 11(Suppl 3):9-18.
12. Basil B, Jordan R, Loveless AH et al. β-Adrenoceptor blocking properties and cardioselectivity of M & B 17,803A. Br J Pharmacol. 1973; 48:198-211. http://www.ncbi.nlm.nih.gov/pubmed/4147427?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1776183&blobtype=pdf
13. Daly MJ, Flook JJ, Levy GP. The selectivity of β-adrenoceptor antagonists on cardiovascular and bronchodilator responses to isoprenaline in the anaesthetized dog. Br J Pharmacol. 1975; 53:173-81. http://www.ncbi.nlm.nih.gov/pubmed/238697?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1666304&blobtype=pdf
14. Harms HH. Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors. J Pharmacol Exp Ther. 1976; 199:329-35. http://www.ncbi.nlm.nih.gov/pubmed/10427?dopt=AbstractPlus
15. Baird JRC, Linnell J. The assessment of β-adrenoceptor blocking potency and cardioselectivity in vitro and in vivo. J Pharm Pharmacol. 1972; 24:880-5.
16. Harms HH, Spoelstra AJG. Cardiac and bronchial β-adrenoceptor antagonistic potencies of atenolol, metoprolol, acebutolol, practolol, propranolol and pindolol in the anaesthetized dog. Clin Exp Pharmacol Physiol. 1978; 5:53-9. http://www.ncbi.nlm.nih.gov/pubmed/25152?dopt=AbstractPlus
17. Briant RH, Dollery CT, George CF. Cardiac and peripheral vascular beta-receptors in the dog and in man: the selectivity of acebutolol (Sectral). Clin Trials J. 1974; 11(Suppl 3):25-8.
18. Bilski A, Robertson HH, Wale JL. A study of the relationship between cardiac β-adrenoceptor blockade and intrinsic sympathomimetic activity in rats depleted of catecholamines. Clin Exp Pharmacol Physiol. 1979; 6:1-9. http://www.ncbi.nlm.nih.gov/pubmed/32980?dopt=AbstractPlus
19. Levy B. The selective beta receptor blocking properties of DL-1-(2-acetyl-4-n-butyramidophenoxy)-2-hydroxy-3- isopropylaminopropane-HCl (M&B 17803-A) in the anesthetized dog. J Pharmacol Exp Ther. 1973; 186:134-44. http://www.ncbi.nlm.nih.gov/pubmed/4146701?dopt=AbstractPlus
20. Dreyer AC, Offermeier J. In vitro assessment of the selectivities of various beta-adrenergic blocking agents. Life Sci. 1980; 27:2087-92. http://www.ncbi.nlm.nih.gov/pubmed/6111008?dopt=AbstractPlus
21. Cuthbert MF, Owusu-Ankomah K. Effect of M & B 17803A, a new β-adrenoceptor blocking agent, on the cardiovascular responses to tilting and to isoprenaline in man. Br J Pharmacol. 1971; 43:639-48. http://www.ncbi.nlm.nih.gov/pubmed/4400530?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1665788&blobtype=pdf
22. Giacomini JC, Thoden WR. Ancillary pharmacologic properties of acebutolol: cardioselectivity, partial agonist activity, and membrane-stabilizing activity. Am Heart J. 1985; 109(5 Part 2):1137-44. http://www.ncbi.nlm.nih.gov/pubmed/2859777?dopt=AbstractPlus
23. Wollam GL, Cody RJ Jr, Tarazi RC et al. Acute hemodynamic effects and cardioselectivity of acebutolol, practolol, and propranolol. Clin Pharmacol Ther. 1979; 25:813-20. http://www.ncbi.nlm.nih.gov/pubmed/445948?dopt=AbstractPlus
24. Mougeot G, Hugues FC, Julien D et al. Influence of propranolol and acebutolol on isoprenaline-induced changes in heart rate and peripheral blood flow in man. Arch Int Pharmacodyn Ther. 1981; 251:116-25. http://www.ncbi.nlm.nih.gov/pubmed/7259364?dopt=AbstractPlus
25. Svendsen TL, Trap-Jensen J, C et al. Immediate central hemodynamic effects of five different beta-adrenoceptor-blocking agents, acebutolol, atenolol, pindolol, practolol, and propranolol, in patients with ischemic heart disease. Am Heart J. 1985; 109(5 Part 2):1145-50. http://www.ncbi.nlm.nih.gov/pubmed/2859778?dopt=AbstractPlus
26. Dreslinski GR, Aristimuno GG, Messerli FH et al. Effects of beta blockade with acebutolol on hypertension, hemodynamics, and fluid volume. Clin Pharmacol Ther. 1979; 26:562-5. http://www.ncbi.nlm.nih.gov/pubmed/498697?dopt=AbstractPlus
27. Nigri A, Mangieri E, Martuscelli E et al. Acute hemodynamic effects of acebutolol and propranolol. Clin Ther. 1984; 6:693-8. http://www.ncbi.nlm.nih.gov/pubmed/6478471?dopt=AbstractPlus
28. Dalal JJ, Ross PJ, Wong K et al. Acute effects of acebutolol on cardiovascular function in man. Br J Clin Pharmacol. 1981; 11:265-8. http://www.ncbi.nlm.nih.gov/pubmed/7213527?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1401624&blobtype=pdf
29. Mason JW, Specter MJ, Ingels NB et al. Haemodynamic effects of acebutolol. Br Heart J. 1978; 40:29-34. http://www.ncbi.nlm.nih.gov/pubmed/341929?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=481970&blobtype=pdf
30. Lewis BS, Bakst A, Mitha AS et al. Haemodynamic effects of a new beta-blocking agent ″Sectral’ (M & B 17803A). Br Heart J. 1973; 35:743-51. http://www.ncbi.nlm.nih.gov/pubmed/4146280?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=458693&blobtype=pdf
31. Ireland MA, Littler WA. The effects of oral acebutolol and propranolol on forearm blood flow in hypertensive patients. Br J Clin Pharmacol. 1981; 12:363-8. http://www.ncbi.nlm.nih.gov/pubmed/7295466?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1401805&blobtype=pdf
32. Joye JA, Lee G, DeMaria AN et al. Afterload advantage of cardioselective beta blockade by acebutolol versus propranolol: hemodynamic assessment by cardiac catheterization in coronary patients. Circulation. 1978; 58:153. http://www.ncbi.nlm.nih.gov/pubmed/647879?dopt=AbstractPlus
33. Ablad B, Brogard M, C et al. β-Adrenergic receptor blocking properties of three allyl-substituted phenoxypropanolamines. Eur J Pharmacol. 1970; 13:59-64. http://www.ncbi.nlm.nih.gov/pubmed/4395676?dopt=AbstractPlus
34. Prichard BNC. β-Adrenergic receptor blockade in hypertension, past, present and future. Br J Clin Pharmacol. 1978; 5:379-99. http://www.ncbi.nlm.nih.gov/pubmed/26370?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1429347&blobtype=pdf
35. Thadani U. Beta blockers in hypertension. Am J Cardiol. 1983; 52:10-5D.
36. Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis. 1976; 19:203-34. http://www.ncbi.nlm.nih.gov/pubmed/10600?dopt=AbstractPlus
37. Shand DG. State-of-the-art: comparative pharmacology of the β-adrenoceptor blocking drugs. Drugs. 1983; 25(Suppl 2):92-9.
38. Breckenridge A. Which beta blocker? Br Med J. 1983; 286:1085-8. (IDIS 169422)
39. Waal-Manning HHJ. The antihypertensive action of several β-adrenoceptor-blocking drugs. N Z Med J. 1976; 83:223-6. http://www.ncbi.nlm.nih.gov/pubmed/8748?dopt=AbstractPlus
40. LeClercq JF, Rosengarten MD, Kural S et al. Effects of intrinsic sympathetic activity of beta-blockers on SA and AV nodes in man. Eur J Cardiol. 1981; 12:367-75. http://www.ncbi.nlm.nih.gov/pubmed/6113145?dopt=AbstractPlus
41. Marrott PK, Ruttley ST, Jenkins PM et al. The electrophysiological evaluation of intravenous acebutolol, a β-blocking drug. Eur J Cardiol. 1977; 6:117-30. http://www.ncbi.nlm.nih.gov/pubmed/913484?dopt=AbstractPlus
42. Amlie JP, Lessum S, Collins RF et al. Plasma levels and electrophysiological effects of acebutolol (M & B 17.803) in the dog heart in situ. Acta Pharmacol Toxicol. 1977; 40:378-88.
43. Kaul S, Hecht HS, Seidman R et al. Comparative effects of oral acebutolol and propranolol at rest and during exercise in ischemic heart disease: double-blind placebo crossover study utilizing radionuclide ventriculography. Am Heart J. 1984; 108:469-74. http://www.ncbi.nlm.nih.gov/pubmed/6382987?dopt=AbstractPlus
44. Rochette L, Didier JP, Moreau D et al. Role of beta-adrenoceptor antagonism in the prevention of reperfusion ventricular arrhythmias: effects of acebutolol, atenolol, and d-propranolol on isolated working rat hearts subject to myocardial ischemia and reperfusion. Am Heart J. 1984; 107:1132-41. http://www.ncbi.nlm.nih.gov/pubmed/6144264?dopt=AbstractPlus
45. Mason JW, Winkle RA, Meffin PJ et al. Electrophysiological effects of acebutolol. Br Heart J. 1978; 40:35-40. http://www.ncbi.nlm.nih.gov/pubmed/341930?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=481971&blobtype=pdf
46. Touboul P, Huerta F, Porte J et al. Etude des proprietes electrophysiologiques de l’acebutolol chez l’homme. (French; with English abstract.) Therapie. 1975; 30:417-27.
47. Chandraratna PAN, Aronow WS, Laddu A. Effects of acebutolol and propranolol on left ventricular performance assessed by echocardiography. Clin Pharmacol Ther. 1980; 27:460-3. http://www.ncbi.nlm.nih.gov/pubmed/7357803?dopt=AbstractPlus
48. Katz RJ, DiBianco R, Singh S et al. Acebutolol and left ventricular function: assessment by radionuclide angiography. Clin Pharmacol Ther. 1981; 29:149-54. http://www.ncbi.nlm.nih.gov/pubmed/7460480?dopt=AbstractPlus
49. Maclagan J, Ney UM. A comparison of the bronchoconstrictor and β-adrenoceptor blocking activity of propranolol and acebutolol. Br J Pharmacol. 1980; 68:196-8. http://www.ncbi.nlm.nih.gov/pubmed/6101978?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2043927&blobtype=pdf
50. Wood AJJ. Pharmacologic differences between beta blockers. Am Heart J. 1984; 108:1070-7. http://www.ncbi.nlm.nih.gov/pubmed/6148865?dopt=AbstractPlus
51. Kumana CR, Kaye CM, Leighton M et al. Cardiac and pulmonary effects of acebutolol. Lancet. 1975; 5:89-93.
52. Benson MK, Berrill WT, Cruickshank JM et al. A comparison of four β-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol. 1978; 5:415-9. http://www.ncbi.nlm.nih.gov/pubmed/26371?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1429350&blobtype=pdf
53. Nair S, Maguire WC, Laddu AR. The effect of acebutolol, a beta adrenergic blocking agent, and placebo on pulmonary functions in asthmatics. Int J Clin Pharmacol Ther Toxicol. 1981; 19:519-26.
54. Gribbin HR, Mackay AD, Baldwin CJ et al. Bronchial and cardiac β-adrenoceptor blockade—a comparison of atenolol, acebutolol and labetalol. Br J Clin Pharmacol. 1981; 12:61-5. http://www.ncbi.nlm.nih.gov/pubmed/6264936?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1401756&blobtype=pdf
55. Mue S, Sasaki T, Ohmi T et al. Influence of acebutolol on the haemodynamic and respiratory function of asthmatic patients. J Pharmacother. 1979; 2:67-71.
56. DiBianco R, Dickie KJ, Singh S et al. Pulmonary effects of acebutolol, a “cardioselective” beta adrenergic blocking agent. Int J Clin Pharmacol Ther Toxicol. 1982; 20:1-7. http://www.ncbi.nlm.nih.gov/pubmed/6120142?dopt=AbstractPlus
57. Greefhorst APM, van Herwaarden CLA. Ventilatory and haemodynamic effects of terbutaline infusion during beta1-selective blockade with metoprolol and acebutolol in asthmatic patients. Eur J Clin Pharmacol. 1982; 23:203-8. http://www.ncbi.nlm.nih.gov/pubmed/6756931?dopt=AbstractPlus
58. Whitsett TL, Levin DC, Manion CV. Comparison of the beta1 and beta2 adrenoceptor blocking properties of acebutolol and propranolol. Chest. 1982; 82:668-73. http://www.ncbi.nlm.nih.gov/pubmed/6128186?dopt=AbstractPlus
59. Greefhorst APM, van Herwaarden CLA. Comparative study of the ventilatory effects of three beta1-selective blocking agents in asthmatic patients. Eur J Clin Pharmacol. 1981; 20:417-21. http://www.ncbi.nlm.nih.gov/pubmed/6116610?dopt=AbstractPlus
60. Leary WP, Coleman AJ, Asmal AC. Respiratory effects of acebutolol hydrochloride: a new selective beta-adrenergic blocking agent. S Afr Med J. 1973; 47:1245-8. http://www.ncbi.nlm.nih.gov/pubmed/4146466?dopt=AbstractPlus
61. Skinner C, Palmer KNV, Kerridge DF. Comparison of the effects of acebutolol (Sectral) and practolol (Eraldin) on airways obstruction in asthmatics. Br J Clin Pharmacol. 1975; 2:417-22. http://www.ncbi.nlm.nih.gov/pubmed/786353?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1402628&blobtype=pdf
62. Skinner C, Palmer KNV. Airways obstruction in asthmatic patients: comparison of the effects of acebutolol, practolol and placebo. Clin Trials J. 1974; 11:29-32.
63. Palmer KNV. Respiratory side effects of beta-blockers. Br Med J. 1977; 1:841.
64. Decalmer PBS, Chatterjee SS, Cruickshank JM et al. Beta-blockers and asthma. Br Heart J. 1978; 40:184-9. http://www.ncbi.nlm.nih.gov/pubmed/25075?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=482795&blobtype=pdf
65. Freed E. Acebutolol-controlled tachycardia in a depressed asthmatic. Med J Aust. 1980; 1:442.
66. Tattersfield AE, Harrison RN. Effect of β-blocker therapy on airway function. Drugs. 1983; 25(Suppl 2):227-31.
67. Gibbons DO, Lant AF, Ashford A et al. Comparative effects of acebutolol and practolol on the lipolytic response to isoprenaline. Br J Clin Pharmacol. 1976; 3:177-84. http://www.ncbi.nlm.nih.gov/pubmed/973938?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1428816&blobtype=pdf
68. Newman RJ. Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia. Br Med J. 1976; 2:447-9. http://www.ncbi.nlm.nih.gov/pubmed/8187?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1687571&blobtype=pdf
69. Lehtonen A. The effect of acebutolol on plasma lipids, blood glucose and serum insulin levels. Acta Med Scand. 1984; 216:57-60. http://www.ncbi.nlm.nih.gov/pubmed/6385635?dopt=AbstractPlus
70. Grimaldi A, Bennett P, Delas B et al. β-Blockers and hypoglycaemia (assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia). Curr Ther Res. 1984; 36:361-73.
71. Covi G, Dalla Riva AD, Pomari S et al. Long-term treatment of essential hypertension with acebutolol: an evaluation of clinical and metabolic effects. Curr Ther Res. 1982; 31:1018-25.
72. Birnbaum J, DiBianco R, Becker KL et al. Glucose and lipid metabolism during acebutolol and propranolol therapy of angina in nondiabetic patients. Clin Pharmacol Ther. 1983; 33:294-300. http://www.ncbi.nlm.nih.gov/pubmed/6337762?dopt=AbstractPlus
73. Frances Y, Luccioni R, Vague P et al. Effects of betaxolol, propranolol, and acebutolol on the glycoregulation after oral glucose tolerance test in hypertensive patients. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:213-20.
74. Deacon SP, Karunanayake A, Barnett D. Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics. Br Med J. 1977; 2:1255-7. http://www.ncbi.nlm.nih.gov/pubmed/338101?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1632423&blobtype=pdf
75. Koch G, Franz IW, Gubba A et al. β-Adrenoceptor blockade and physical activity: cardiovascular and metabolic aspects. Acta Med Scand. 1983; 672(Suppl):55-62.
76. Barnett AH, Leslie D, Watkins PJ. Can insulin-treated diabetics be given beta-adrenergic blocking drugs? Br Med J. 1980; 280:976-8.
77. Leary WP. The cardioselectivity of acebutolol (Sectral) in man. Clin Trials J. 1974; 11(Suppl 3):33-5.
78. James I. The beta-blocker dilemma. Geriatric Med. 1983; 13:429-30.
79. Giuntoli F, Scalabrino A, Galeone F et al. Antihypertensive and metabolic effects of a long-term treatment with acebutolol. Curr Ther Res. 1984; 36:188-94.
80. Newman RJ. Comparison of the antilipolytic effect of metoprolol, acebutolol, and propranolol in man. Br Med J. 1977; 2:601-3. http://www.ncbi.nlm.nih.gov/pubmed/901996?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1631536&blobtype=pdf
81. Lehtonen A. Effect of beta blockers on blood lipid profile. Am Heart J. 1985; 109(5 Part 2):1192-6. http://www.ncbi.nlm.nih.gov/pubmed/2859784?dopt=AbstractPlus
82. Harms HH, Gooren L, Spoelstra AJG et al. Blockade of isoprenaline-induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma renin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol. Br J Clin Pharmacol. 1978; 5:19-26. http://www.ncbi.nlm.nih.gov/pubmed/23133?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1429223&blobtype=pdf
83. Lewis MJ, Groom GV, Barber R et al. The effects of propranolol and acebutolol on the overnight plasma levels of anterior pituitary and related hormones. Br J Clin Pharmacol. 1981; 12:737-42. http://www.ncbi.nlm.nih.gov/pubmed/6800389?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1401950&blobtype=pdf
84. Jones MK, John R, Jones GR. The effect of oxprenolol, acebutolol and propranolol on thyroid hormones in hyperthyroid subjects. Clin Endocrinol. 1980; 13:343-7.
85. Collett JT, Hendrickson JA, Chew YC et al. Comparative beta-blocking potencies of acebutolol and propranolol relative to plasma drug levels. Int J Clin Pharmacol Ther Toxicol. 1981; 19:473-8. http://www.ncbi.nlm.nih.gov/pubmed/6117519?dopt=AbstractPlus
86. de Villiers AS, Folb PI, Pascoe M et al. Pharmacokinetics of acebutolol and its acetyl metabolite, diacetolol, in hypertensive patients and in renal use. S Afr J Sci. 1981; 77:286.
87. George CF, Gruchy BS. Elimination of drugs by active intestinal transport. J Pharm Pharmacol. 1979; 31:643-4. http://www.ncbi.nlm.nih.gov/pubmed/41074?dopt=AbstractPlus
88. Cockburn JJ. Which beta blocker? Br Med J. 1983; 286:1439. Letter.
89. Feely J, Maclean D. New drugs: beta blockers and sympathomimetics. BMJ. 1983; 286:1972. http://www.ncbi.nlm.nih.gov/pubmed/6407660?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1548319&blobtype=pdf
90. Winkle RA, Meffin PJ, Ricks WB et al. Acebutolol metabolite plasma concentration during chronic oral therapy. Br J Clin Pharmacol. 1977; 4:519-22. http://www.ncbi.nlm.nih.gov/pubmed/911602?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1429145&blobtype=pdf
91. Martin MA, Phillips FC, Tucker GT et al. Acebutolol in hypertension: relationships between drug concentration and effects. Eur J Clin Pharmacol. 1978; 14:383-90. http://www.ncbi.nlm.nih.gov/pubmed/367793?dopt=AbstractPlus
92. Kaye CM. The biliary excretion of acebutolol in man. J Pharm Pharmacol. 1976; 28:449-50. http://www.ncbi.nlm.nih.gov/pubmed/6757?dopt=AbstractPlus
93. Meffin PJ, Winkle RA, Peters FA et al. Acebutolol disposition after intravenous administration. Clin Pharmacol Ther. 1977; 22:557-67. http://www.ncbi.nlm.nih.gov/pubmed/913023?dopt=AbstractPlus
94. Meffin PJ, Winkle RA, Peters FA et al. Dose-dependent acebutolol disposition after oral administration. Clin Pharmacol Ther. 1978; 24:542-7. http://www.ncbi.nlm.nih.gov/pubmed/699478?dopt=AbstractPlus
95. Gulaid AA, James IM, Kaye CM et al. The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.) Biopharm Drug Dispos. 1981; 2:103-14.
96. de Soyza ND, Murphy ML, O’Riley M et al. Correlation of antiarrhythmic activity of acebutolol with blood levels and heart rate. Clin Pharmacol Ther. 1982; 31:217.
97. Roux A, Flouvat B, Fouache Y et al. Systemic bioavailability of acebutolol in man. Biopharm Drug Dispos. 1983; 4:293-7. http://www.ncbi.nlm.nih.gov/pubmed/6626703?dopt=AbstractPlus
98. Cuthbert MF, Collins RF. Plasma levels and β-adrenoceptor blockade with acebutolol, practolol and propranolol in man. Br J Clin Pharmacol. 1975; 2:49-55. http://www.ncbi.nlm.nih.gov/pubmed/1234486?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1402490&blobtype=pdf
99. Meffin PJ, Harapat SR, Harrison DC. Quantitation in plasma and urine of acebutolol and a major metabolite with preliminary observations on their disposition kinetics in man. Res Commun Chem Pathol Pharmacol. 1976; 15:31-51. http://www.ncbi.nlm.nih.gov/pubmed/968178?dopt=AbstractPlus
100. Watson RDS, Littler WA. Onset and duration of β-adrenergic receptor blockade following single oral dose acebutolol hydrochloride (Sectral). Br J Clin Pharmacol. 1979; 7:557-61. http://www.ncbi.nlm.nih.gov/pubmed/37868?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1429672&blobtype=pdf
101. Zaman R, Wilkins MR, Kendall MJ et al. The effect of food and alcohol on the pharmacokinetics of acebutolol and its metabolite, diacetolol. Biopharm Drug Dispos. 1984; 5:91-5. http://www.ncbi.nlm.nih.gov/pubmed/6704510?dopt=AbstractPlus
102. Kaye CM, Kumana CR, Leighton M et al. Observations on the pharmacokinetics of acebutolol. Clin Pharmacol Ther. 1976; 19:416-20. http://www.ncbi.nlm.nih.gov/pubmed/1269192?dopt=AbstractPlus
103. Coombs TJ, Coulson CJ, Smith VJ. Blood plasma binding of acebutolol and diacetolol in man. Br J Clin Pharmacol. 1980; 9:395-7. http://www.ncbi.nlm.nih.gov/pubmed/7378256?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1429991&blobtype=pdf
104. Zaman R, Jack DB, Kendall MJ. The penetration of acebutolol and its major metabolite, diacetolol, into human cerebrospinal fluid and saliva. Br J Clin Pharmacol. 1981; 12:427-9. http://www.ncbi.nlm.nih.gov/pubmed/7295474?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1401814&blobtype=pdf
105. Bianchetti G, Boutroy MJ, Dubruc C et al. Placental transfer and pharmacokinetics of acebutolol and N-acetyl acebutolol in the newborn. Br J Pharmacol. 1981; 72:135-6P.
106. Bianchetti G, Dubruc C, Vert P et al. Placental transfer and pharmacokinetics of acebutolol in newborn infants. Clin Pharmacol Ther. 1981; 29:233-4.
107. Daffos F, Freund M, Sarrot G et al. Passage transplacentaire de l’acebutolol et du diacetolol. Nouv Presse Med. 1982; 11:2154-5.
108. Alexander MS, Bianchine JR. Acebutolol kinetics following oral and intravenous administration in man. Clin Pharmacol Ther. 1984; 35:225.
109. Gabriel R, Kaye CM, Sankey MG. Preliminary observations on the excretion of acebutolol and its acetyl metabolite in the urine and faeces of man. J Pharm Pharmacol. 1981; 33:386-7. http://www.ncbi.nlm.nih.gov/pubmed/6115014?dopt=AbstractPlus
110. Andresen BD, Davis FT. Metabolism of acebutolol-d6 in the rat correlates with the identification of a new metabolite in human urine. Drug Metab Dispos. 1979; 79:360-5.
111. Collins RF, George CF. Studies on the disposition and fate of [14C]-acebutolol in man and dog. Br J Clin Pharmacol. 1976; 3:346-7P.
112. Roux A, Flouvat B, Chau NP et al. Pharmacokinetics of acebutolol after intravenous bolus administration. Br J Clin Pharmacol. 1980; 9:215-7. http://www.ncbi.nlm.nih.gov/pubmed/7356910?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1429864&blobtype=pdf
113. Gulaid A, James IM, Kaye CM et al. Lack of correlation between acetylator status and the production of the acetyl metabolite of acebutolol in man. Br J Clin Pharmacol. 1978; 5:261-2. http://www.ncbi.nlm.nih.gov/pubmed/656272?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1429267&blobtype=pdf
114. Basil B, Jordan R. Pharmacological properties of diacetolol (M&B 16,942), a major metabolite of acebutolol. Eur J Pharmacol. 1982; 80:47-56. http://www.ncbi.nlm.nih.gov/pubmed/6124437?dopt=AbstractPlus
115. Thomas MS, Tattersfield AE. Comparison of beta-adrenoceptor selectivity of acebutolol and its metabolite diacetolol with metoprolol and propranolol in normal man. Eur J Clin Pharmacol. 1986; 29:679-83. http://www.ncbi.nlm.nih.gov/pubmed/2872056?dopt=AbstractPlus
116. Ohashi K, Warrington SJ, Kaye CM et al. Observations on the clinical pharmacology and plasma concentrations of diacetolol, the major human metabolite of acebutolol. Br J Clin Pharmacol. 1981; 12:561-5. http://www.ncbi.nlm.nih.gov/pubmed/7295489?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1401897&blobtype=pdf
117. Flouvat B, Roux A, Delhotal B et al. The beta-blocking effect of diacetolol in humans and its relationship to plasma levels. Int J Clin Pharmacol Ther Toxicol. 1982; 20:358-61. http://www.ncbi.nlm.nih.gov/pubmed/6126441?dopt=AbstractPlus
118. Flouvat B, Roux A, Chau NP et al. Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. Eur J Clin Pharmacol. 1981; 19:287-92. http://www.ncbi.nlm.nih.gov/pubmed/7286031?dopt=AbstractPlus
119. Kaye CM. New drugs: beta blockers and sympathomimetics. BMJ. 1983; 286:1439. http://www.ncbi.nlm.nih.gov/pubmed/6404493?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1547844&blobtype=pdf
120. Feely J, deVane PJ, Maclean D. Beta-blockers and sympathomimetics. BMJ. 1983; 286:1043-7. http://www.ncbi.nlm.nih.gov/pubmed/6131725?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1547508&blobtype=pdf
121. Kaye CM, Long AD. The influence of pH on the buccal absorption and plasma and renal elimination of acebutolol. Br J Clin Pharmacol. 1976; 3:196-7. http://www.ncbi.nlm.nih.gov/pubmed/9955?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1428818&blobtype=pdf
122. Roux A, Henry JF, Fouache Y et al. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. Gerontology. 1983; 29:202-8. http://www.ncbi.nlm.nih.gov/pubmed/6852547?dopt=AbstractPlus
123. Munn S, Bailey RR, Begg E et al. Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment. N Z Med J. 1980; 91:289-91. http://www.ncbi.nlm.nih.gov/pubmed/6930006?dopt=AbstractPlus
124. Kirch W, Kohler H, Berggren G et al. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite. Clin Nephrol. 1982; 18:88-94. http://www.ncbi.nlm.nih.gov/pubmed/7140021?dopt=AbstractPlus
125. Roux A, Aubert P, Guedon J et al. Pharmacokinetics of acebutolol in patients with all grades of renal failure. Eur J Clin Pharmacol. 1980; 17:339-48. http://www.ncbi.nlm.nih.gov/pubmed/7418713?dopt=AbstractPlus
126. Kaye CM, Dufton JF. Preliminary observations on the elimination of acebutolol in severe chronic renal failure. Br J Clin Pharmacol. 1976; 3:198-9. http://www.ncbi.nlm.nih.gov/pubmed/788740?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1428803&blobtype=pdf
127. Smith RS, Warren DJ, Renwick AG et al. Acebutolol pharmacokinetics in renal failure. Br J Clin Pharmacol. 1983; 16:253-8. http://www.ncbi.nlm.nih.gov/pubmed/6626416?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1427998&blobtype=pdf
128. Zaman R, Jack DB, Wilkins MR et al. Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: a single dose study. Biopharm Drug Dispos. 1985; 6:131-7. http://www.ncbi.nlm.nih.gov/pubmed/4005393?dopt=AbstractPlus
129. Esler M, Zweifler A, Randall O et al. Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol. Clin Pharmacol Ther. 1978; 22:299-308.
130. Collste P, Haglund K, Frisk-Holmberg M et al. Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. Eur J Clin Pharmacol. 1976; 10:89-95. http://www.ncbi.nlm.nih.gov/pubmed/964292?dopt=AbstractPlus
131. Gibson TP, Matusik E, Nelson LD et al. Artificial kidneys and clearance calculations. Clin Pharmacol Ther. 1976; 20:720-6. http://www.ncbi.nlm.nih.gov/pubmed/991541?dopt=AbstractPlus
132. Pond S, Rosenberg J, Benowitz NL et al. Pharmacokinetics of haemoperfusion for drug overdose. Clin Pharmacokinet. 1979; 4:329-54. http://www.ncbi.nlm.nih.gov/pubmed/389527?dopt=AbstractPlus
133. Lee CSC, Marbury TC. Drug therapy in patients undergoing haemodialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet. 1984; 9:42-66. http://www.ncbi.nlm.nih.gov/pubmed/6362952?dopt=AbstractPlus
134. Pond SM. Renal principles: diuresis, dialysis, and hemoperfusion. In: Goldfrank’s toxicologic emergencies. 3rd ed. Norwalk, CT: Appleton-Century-Crofts; 1986:102-15.
135. Jack DB, Quarterman CP, Zaman R et al. Variability of beta-blocker pharmacokinetics in young volunteers. Eur J Clin Pharmacol. 1982; 23:37-42. http://www.ncbi.nlm.nih.gov/pubmed/6127220?dopt=AbstractPlus
136. Tjandramaga TB. Altered pharmacokinetics of β-adrenoceptor blocking drugs in patients with renal insufficiency. Arch Int Pharmacodyn Ther. 1980; 247(Suppl):38-53.
137. Gradman AH, Winkle RA, Fitzgerald JW et al. Suppression of premature ventricular contractions by acebutolol. Circulation. 1977; 55:785-91. http://www.ncbi.nlm.nih.gov/pubmed/66105?dopt=AbstractPlus
138. DiBianco R, Singh SN, Shah PM et al. Comparison of the antianginal efficacy of acebutolol and propranolol. Circulation. 1982; 65:119-28.
139. Fournier A, Hardin JM, Alexandre JM et al. Anti-hypertensive effect of acebutolol: its relation to sympathetic nervous system responsiveness and to plasma renin and dopamine-β-hydroxylase activities. Clin Sci Mol Med. 1976; 51:477-80s.
140. Martin MA, Phillips CA, Smith AJ. Acebutolol in hypertension—a double-blind trial against placebo. Br J Clin Pharmacol. 1978; 6:351-6. http://www.ncbi.nlm.nih.gov/pubmed/359018?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1429467&blobtype=pdf
141. Menard J, Bertagna X, N’Guyen PT et al. Rapid identification of patients with essential hypertension sensitive to acebutolol (a new cardioselective beta-blocker). Am J Med. 1976; 60:886-90. http://www.ncbi.nlm.nih.gov/pubmed/14503?dopt=AbstractPlus
142. Belleau LJ, Lebel M, Brossard JJ. Merits of adding a beta blocker (acebutolol) to a diuretic (hydrochlorothiazide) in the treatment of hypertension. J Clin Pharmacol. 1982; 22:20-7. http://www.ncbi.nlm.nih.gov/pubmed/7037871?dopt=AbstractPlus
143. Alhenc-Gelas F, Plouin PF, Ducrocq MB et al. Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension. Am J Med. 1978; 64:1005-12. http://www.ncbi.nlm.nih.gov/pubmed/655186?dopt=AbstractPlus
144. Gorkin JU, Elijovich F, Dziedzic SW et al. Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981; 30:739-44. http://www.ncbi.nlm.nih.gov/pubmed/6118215?dopt=AbstractPlus
145. Thibonnier M, Lardoux MD, Corvol P. Comparative trial of labetalol and acebutolol, alone or associated with dihydralazine, in treatment of essential hypertension. Br J Clin Pharmacol. 1980; 9:561-7. http://www.ncbi.nlm.nih.gov/pubmed/6992823?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1430010&blobtype=pdf
146. Begg E, Munn S, Bailey RR. Acebutolol in the treatment of patients with hypertension and renal functional impairment. N Z Med J. 1979; 89:293-5. http://www.ncbi.nlm.nih.gov/pubmed/286923?dopt=AbstractPlus
147. Heel RC, Brogden RN, Speight TM et al. Atenolol: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs. 1979; 17:425-60. http://www.ncbi.nlm.nih.gov/pubmed/38096?dopt=AbstractPlus
148. Merck Sharp & Dohme. Blocadren prescribing information. West Point, PA; 1985 Apr.
149. Gabriel R. Acebutolol in the management of hypertension in patients with renal disease. Br J Clin Pract. 1979; 33:259-62. http://www.ncbi.nlm.nih.gov/pubmed/486303?dopt=AbstractPlus
150. Wahl J, Singh BN, Thoden WR. Comparative hypotensive effects of acebutolol and hydrochlorothiazide in patients with mild to moderate essential hypertension: a double-blind multicenter evaluation. Am Heart J. 1986; 111:353-62. http://www.ncbi.nlm.nih.gov/pubmed/3511650?dopt=AbstractPlus
151. Hansson L, Berglund G, Andersson O et al. Controlled trial of acebutolol in hypertension. Eur J Clin Pharmacol. 1977; 12:89-92. http://www.ncbi.nlm.nih.gov/pubmed/336378?dopt=AbstractPlus
152. Wahl J, Turlapaty P, Singh BN et al. Comparison of acebutolol and propranolol in essential hypertension. Am Heart J. 1985; 109:313-21. http://www.ncbi.nlm.nih.gov/pubmed/3880995?dopt=AbstractPlus
153. Singh AN, Paul L, Brossard JJ. Double-blind cross-over study of two beta-blocking agents acebutolol and propranolol in essential hypertension. Curr Ther Res. 1980; 28:964-71.
154. Davidov M. Acebutolol in essential hypertension: results of two multicenter studies against placebo and propranolol. Am Heart J. 1985; 109(5 Part 2):1158-67. http://www.ncbi.nlm.nih.gov/pubmed/2859780?dopt=AbstractPlus
155. Manttari M, Eisalo A. A comparison of two cardioselective beta-blockers with different ancillary properties in the treatment of hypertension. Acta Med Scand. 1982; 668(Suppl):114-7.
156. Turner AS, Brocklehurst JC. Once-daily acebutolol and atenolol in essential hypertension: double-blind crossover comparison. Am Heart J. 1985; 109(5 Part 2):1178-83. http://www.ncbi.nlm.nih.gov/pubmed/3993534?dopt=AbstractPlus
157. Hua ASP, Kalowski S, Whitworth JA et al. Acebutolol in mild to moderate hypertension. Med J Aust. 1980; 1:226-8. http://www.ncbi.nlm.nih.gov/pubmed/6990216?dopt=AbstractPlus
158. Baker PG, Goulton J. A multicentre study of a once daily dosage of acebutolol in the treatment of hypertension in general practice. J Int Med Res. 1979; 7:201-14. http://www.ncbi.nlm.nih.gov/pubmed/456733?dopt=AbstractPlus
159. Nadeau J, Ogilvie RI, Ruedy J et al. Acebutolol and hydrochlorothiazide in essential hypertension. Clin Pharmacol Ther. 1980; 28:296-301. http://www.ncbi.nlm.nih.gov/pubmed/7408389?dopt=AbstractPlus
160. Franz IW. Differential antihypertensive effect of acebutolol and hydrochlorothiazide/amiloride hydrochloride combination on elevated exercise blood pressures in hypertensive patients. Am J Cardiol. 1980; 46:301-5. http://www.ncbi.nlm.nih.gov/pubmed/6105821?dopt=AbstractPlus
161. Leary WP, Asmal AC, Williams PC. Aldactone and acebutolol in treatment of hypertension. J Int Med Res. 1979; 7:29-32. http://www.ncbi.nlm.nih.gov/pubmed/369923?dopt=AbstractPlus
162. Khalil SI, El Zein O, Bella ME. A double-blind, crossover study of acebutolol and hydrochlorothiazide/amiloride diuretic in Sudanese patients with essential hypertension. Curr Med Res Opin. 1982; 8:39-43. http://www.ncbi.nlm.nih.gov/pubmed/7049584?dopt=AbstractPlus
163. Oli JM. Acebutolol in the management of hypertension in Nigerians. Curr Ther Res. 1981; 30:477-82.
164. MacGregor GA, Banks RA, Markandu ND et al. Lack of effect of beta-blocker on flat dose response to thiazide in hypertension: efficacy of low dose thiazide combined with beta-blocker. BMJ. 1983; 286:1535-8. http://www.ncbi.nlm.nih.gov/pubmed/6405876?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1548006&blobtype=pdf
165. Nievel JG, Havard CWH. Assessment of the efficacy and acceptability of an acebutolol/hydrochlorothiazide combination in the treatment of mild to moderate essential hypertension. Curr Med Res Opin. 1981; 7:526-35. http://www.ncbi.nlm.nih.gov/pubmed/7030637?dopt=AbstractPlus
166. Mitenko PA, McKenzie JK, Brossard JJ. Antihypertensive action of acebutolol (Sectral) when used concomitantly with hydrochlorothiazide. Br J Clin Pharmacol. 1982; 13:209-12. http://www.ncbi.nlm.nih.gov/pubmed/7059418?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1401992&blobtype=pdf
167. Ogilvie RI, Nadeau JH. Cardiovascular effects of acebutolol and hydrochlorothiazide in essential hypertension. Hypertension. 1982; 4:320-4. http://www.ncbi.nlm.nih.gov/pubmed/7040230?dopt=AbstractPlus
168. Down PF, Rao SK, Braverman AM et al. Treatment of hypertension in the elderly with a low dose combination of a beta-adrenoceptor blocker and a thiazide diuretic: comparison with methyldopa. Br J Clin Pract. 1983; 37:371-4,88. http://www.ncbi.nlm.nih.gov/pubmed/6367793?dopt=AbstractPlus
169. Fraser DM, Nimmo GR, Poloniecki JD. Acebutolol in the treatment of diabetic patients with hypertension. Curr Med Res Opin. 1986; 10:122-7. http://www.ncbi.nlm.nih.gov/pubmed/3519092?dopt=AbstractPlus
170. Boyles PW. Effects of age and race on clinical response to acebutolol in essential hypertension. Am Heart J. 1985; 109(5 Part 2):1184-92. http://www.ncbi.nlm.nih.gov/pubmed/2859783?dopt=AbstractPlus
171. Costa FV, Caldari R, Borghi C et al. Acebutolol, atenolol and nadolol: comparison of their antihypertensive efficacy at rest and during exercise. Curr Ther Res. 1984; 35:961-73.
173. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1984; 26:107-12. http://www.ncbi.nlm.nih.gov/pubmed/6150424?dopt=AbstractPlus
174. Moser M. Initial treatment of adult patients with essential hypertension. Part I: why conventional stepped-care therapy of hypertension is still indicated. Pharmacotherapy. 1985; 5:189-95. http://www.ncbi.nlm.nih.gov/pubmed/2863806?dopt=AbstractPlus
175. Kaplan NM. Initial treatment of adult patients with essential hypertension. Part II: alternating monotherapy is the preferred treatment. Pharmacotherapy. 1985; 5:195-200. http://www.ncbi.nlm.nih.gov/pubmed/4034407?dopt=AbstractPlus
176. World Health Organization/International Society of Hypertension Fourth Mild Hypertension Conference. 1986 guidelines for the treatment of mild hypertension: memorandum from the WHO/ISH. Hypertension. 1986; 8:957-61.
178. Weiner N. Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:181-214.
179. Rudd P, Blaschke TF. Antihypertensive agents and the drug therapy of hypertension. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:784-805.
180. Kaplan NM. Mild hypertension: when and how to treat. Arch Intern Med. 1983; 143:255-9. http://www.ncbi.nlm.nih.gov/pubmed/6130750?dopt=AbstractPlus
181. Kaplan NM. Non-drug treatment of hypertension. Ann Intern Med. 1985; 102:359-73. http://www.ncbi.nlm.nih.gov/pubmed/3882040?dopt=AbstractPlus
182. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Return of elevated blood pressure after withdrawal of antihypertensive drugs. Circulation. 1975; 51:1107-13. http://www.ncbi.nlm.nih.gov/pubmed/1093758?dopt=AbstractPlus
183. Kaplan NM. New choices for the initial drug therapy of hypertension. Am J Cardiol. 1983; 51:1786-8. http://www.ncbi.nlm.nih.gov/pubmed/6134465?dopt=AbstractPlus
184. Lewis JE. Comparison of acebutolol and hydrochlorothiazide in essential hypertension. Am Heart J. 1985; 109(5 Part 2):1168-74. http://www.ncbi.nlm.nih.gov/pubmed/2859781?dopt=AbstractPlus
185. de Soyza N, Shapiro W, Chandraratna PAN et al. Acebutolol therapy for ventricular arrhythmia: a randomized, placebo-controlled, double-blind multicenter study. Circulation. 1982; 65:1129-33. http://www.ncbi.nlm.nih.gov/pubmed/7042111?dopt=AbstractPlus
186. Lui HK, Lee G, Dhurandhar R et al. Reduction of ventricular ectopic beats with oral acebutolol: a double-blind, randomized crossover study. Am Heart J. 1983; 105:722-6. http://www.ncbi.nlm.nih.gov/pubmed/6846115?dopt=AbstractPlus
187. Burckhardt D, Raeder EA. The effect of acebutolol on cardiac arrhythmias in patients with chronic coronary artery disease. Am Heart J. 1980; 99:443-5. http://www.ncbi.nlm.nih.gov/pubmed/6102434?dopt=AbstractPlus
188. Peretz DI, McMurtry TJ. Evaluation of the clinical effectiveness of acebutolol, a cardio-specific beta-adrenergic blocking agent, in the suppression of premature ventricular contractions. Curr Ther Res. 1979; 26:557-61.
189. Singh SN, DiBianco R, Davidov ME et al. Comparison of acebutolol and propranolol for treatment of chronic ventricular arrhythimia: a placebo-controlled, double-blind, randomized crossover study. Circulation. 1982; 65:1356-64. http://www.ncbi.nlm.nih.gov/pubmed/6176357?dopt=AbstractPlus
190. Shapiro W, Park J, Koch GG. Variability of spontaneous and exercise-induced ventricular arrhythmias in the absence and presence of treatment with acebutolol or quinidine. Am J Cardiol. 1982; 49:445-54. http://www.ncbi.nlm.nih.gov/pubmed/6174041?dopt=AbstractPlus
191. Labram C. Control of cardiac arrhythmias: the use of acebutolol. Clin Trials J. 1974; 3:115-20.
192. Williams DO, Tatelbaum R, Most AS. Effective treatment of supraventricular arrhythmias with acebutolol. Am J Cardiol. 1979; 44:521-5. http://www.ncbi.nlm.nih.gov/pubmed/382821?dopt=AbstractPlus
193. Ahumada GG, Karlsberg RP, Jaffe AS et al. Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction. Br Heart J. 1979; 41:654-9. http://www.ncbi.nlm.nih.gov/pubmed/465240?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=482087&blobtype=pdf
194. de Soyza N, Kane JJ, Murphy ML et al. The long-term suppression of ventricular arrhythmia by oral acebutolol in patients with coronary artery disease. Am Heart J. 1980; 100:631-8. http://www.ncbi.nlm.nih.gov/pubmed/6778183?dopt=AbstractPlus
195. de Soyza N. Acebutolol for premature ventricular contractions: short- and long-term effects. Am Heart J. 1985; 109(5 Part 2):1205-9. http://www.ncbi.nlm.nih.gov/pubmed/3993536?dopt=AbstractPlus
196. Khambatta RB. Clinical tachydysrhythmias: the effect of acebutolol (Sectral) on tachydysrhythmias in general and after myocardial infarction. Clin Trials J. 1971; 11:109-14.
197. Aronow WS, Turbow M, Lurie M et al. Treatment of premature ventricular complexes with acebutolol. Am J Cardiol. 1979; 43:106-8. http://www.ncbi.nlm.nih.gov/pubmed/758758?dopt=AbstractPlus
198. Chandraratna PAN. Comparison of acebutolol with propranolol, quinidine, and placebo: results of three multicenter arrhythmia trials. Am Heart J. 1985; 109(5 Part 2):1198-204. http://www.ncbi.nlm.nih.gov/pubmed/3993535?dopt=AbstractPlus
199. Glasser SP, Clark PI, Laddu AR. Comparison of the antiarrhythmic effects of acebutolol and propranolol in the treatment of ventricular arrhythmias. Am J Cardiol. 1983; 52:992-5. http://www.ncbi.nlm.nih.gov/pubmed/6195911?dopt=AbstractPlus
200. Aronow WS, Van Camp S, Turbow M et al. Acebutolol in supraventricular arrhythmias. Clin Pharmacol Ther. 1979; 25:149-53. http://www.ncbi.nlm.nih.gov/pubmed/365429?dopt=AbstractPlus
201. Aronow WS, Wong R, Plasencia G et al. Effect of acebutolol and propranolol on premature ventricular complexes. Clin Pharmacol Ther. 1980; 28:28-31. http://www.ncbi.nlm.nih.gov/pubmed/6993085?dopt=AbstractPlus
202. Letac B. Treatment of cardiac arrhythmias: use of intravenous acebutolol. Clin Trials J. 1974; 11:105-8.
203. Gotsman MS, Lewis BS, Mitha AS. Acebutolol (Sectral) in the treatment of cardiac arrhythmias. Clin Trials J. 1974; 11:121-6.
204. Platia EV, Berdoff R, Stone G et al. Comparison of acebutolol and propranolol therapy for ventricular arrhythmias. J Clin Pharmacol. 1985; 25:130-7. http://www.ncbi.nlm.nih.gov/pubmed/2580866?dopt=AbstractPlus
205. DiBianco R, Singh S, Singh JB et al. Effects of acebutolol on chronic stable angina pectoris: a placebo-controlled, double-blind, randomized crossover study. Circulation. 1980; 62:1179-87. http://www.ncbi.nlm.nih.gov/pubmed/6777070?dopt=AbstractPlus
206. Lee G, DeMaria AN, Favrot L et al. Efficacy of acebutolol in chronic stable angina using single-blind and randomized double-blind protocol. J Clin Pharmacol. 1982; 22:371-8. http://www.ncbi.nlm.nih.gov/pubmed/6813360?dopt=AbstractPlus
207. Tremblay G, Biron P, Proulx A. Acebutolol: efficacy of a single daily dose in angina pectoris. Curr Ther Res. 1979; 25:637-40.
208. Tremblay G, Biron P, Caille G et al. Double-blind crossover trial of single- versus twice-daily doses of acebutolol in angina. Curr Ther Res. 1981; 29:644-50.
209. Rod JL, Admon D, Kimchi A et al. Evaluation of the beta-blocking drug acebutolol in angina pectoris. Am Heart J. 1979; 98:604-12. http://www.ncbi.nlm.nih.gov/pubmed/495406?dopt=AbstractPlus
210. Macdonald IL, Culbert PS, Robertson JW et al. A comparison study of acebutolol, a cardiospecific β-adrenergic blocker, and propranolol in the treatment of angina pectoris. Curr Ther Res. 1978; 24:470-8.
211. DiBianco R, Singh SN, Shah PM et al. Comparison of the antianginal efficacy of acebutolol and propranolol: a multicenter, randomized, double-blind placebo-controlled study. Circulation. 1982; 65:1119-28. http://www.ncbi.nlm.nih.gov/pubmed/6804109?dopt=AbstractPlus
212. Ross MB, Levine P. A double-blind cross-over evaluation of acebutolol and propranolol in patients with angina pectoris. Curr Ther Res. 1981; 29:202-7.
213. Biron P, Tremblay G, Proulx A. Double-blind crossover comparison of acebutolol and propranolol in angina. Clin Pharmacol Ther. 1978; 23:109.
214. Rotem CE, Carruthers J, Byrne A. Long-term management of angina pectoris with acebutolol. Curr Ther Res. 1979; 26:562-7.
215. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305:500-6. http://www.ncbi.nlm.nih.gov/pubmed/6114433?dopt=AbstractPlus
216. Opie LH. Drugs and the heart. Lancet. 1980; 1:693-8. http://www.ncbi.nlm.nih.gov/pubmed/6103100?dopt=AbstractPlus
217. Leonard RG, Talbert RL. Calcium-channel blocking agents. Clin Pharm. 1982; 1:17-33. http://www.ncbi.nlm.nih.gov/pubmed/6764159?dopt=AbstractPlus
218. K.dtdberg RP. Calcium channel blockers for cardiovascular disorders. Arch Intern Med. 1982; 142:452-5.
219. Zelis R. Calcium-blocker therapy for unstable angina pectoris. N Engl J Med. 1982; 306:926-8. http://www.ncbi.nlm.nih.gov/pubmed/6121290?dopt=AbstractPlus
220. Biron P, Tremblay G. Differential antianginal responsiveness to acebutolol. Eur J Clin Pharmacol. 1975; 8:15-9. http://www.ncbi.nlm.nih.gov/pubmed/786672?dopt=AbstractPlus
221. Kimchi A, Gotsman MS, Lewis BS. Acebutolol in angina pectoris: objective assessment using graded treadmill testing. Isr J Med Sci. 1978; 14:941-7. http://www.ncbi.nlm.nih.gov/pubmed/363642?dopt=AbstractPlus
222. Gotsman MS, Lewis BS. The treatment of angina pectoris: an objective assessment of oral acebutolol (Sectral). Clin Trials J. 1974; 11(Suppl 3):80-5.
223. Pfisterer M, Muller-Brand J, Burkart F. Combined acebutolol/nifedipine therapy in patients with chronic coronary artery disease: additional improvement of ischemia-induced left ventricular dysfunction. Am J Cardiol. 1982; 49:1259-66. http://www.ncbi.nlm.nih.gov/pubmed/7064850?dopt=AbstractPlus
224. Steele P, Gold F. Favorable effects of acebutolol on exercise performance and angina in men with coronary artery disease. Chest. 1982; 82:40-3. http://www.ncbi.nlm.nih.gov/pubmed/7044708?dopt=AbstractPlus
225. De Ponti C, De Biase AM, Cataldo G et al. Effects of nifedipine, acebutolol, and their association on exercise tolerance in patients with effort angina. Cardiology. 1981; 68(Suppl 2):195-9. http://www.ncbi.nlm.nih.gov/pubmed/7032697?dopt=AbstractPlus
226. Geigy Pharmaceuticals. Lopressor prescribing information. In: Huff BB, ed. Physicians’ desk reference. 41st ed. Oradell, NJ: Medical Economics Company Inc; 1987:956-60.
227. Booth RJ, Wilson JD, Bullock JY. β-Adrenergic-receptor blockers and antinuclear antibodies in hypertension. Clin Pharmacol Ther. 1982; 31:555-63. http://www.ncbi.nlm.nih.gov/pubmed/6122525?dopt=AbstractPlus
228. Akoun GM, Herman DP, Mayaud CM et al. Acebutolol-induced hypersensitivity pneumonitis. BMJ. 1983; 286:266-7. http://www.ncbi.nlm.nih.gov/pubmed/6402066?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1546532&blobtype=pdf
229. Akoun GM, Mayaud CM, Milleron BJ et al. Drug-related pneumonitis and drug-induced hypersensitivity pneumonitis. Lancet. 1984; 1:1362. http://www.ncbi.nlm.nih.gov/pubmed/6145066?dopt=AbstractPlus
230. Cody RJ Jr, Calabrese LH, Clough JD et al. Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther. 1979; 25:800-5. http://www.ncbi.nlm.nih.gov/pubmed/87291?dopt=AbstractPlus
231. Tirlapur VG, Evans PJ, Jones MK. Shock syndrome after acebutolol. Br J Clin Pract. 1986; 40:33-4. http://www.ncbi.nlm.nih.gov/pubmed/3707825?dopt=AbstractPlus
232. Piette JC, Bourgeois P, Herson S et al. Acebutolol-induced lupus (AIL). Arthritis Rheum. 1985; 28(Suppl 4S):S52.
233. Record NB Jr. Acebutolol-induced pleuropulmonary lupus syndrome. Ann Intern Med. 1981; 95:326-7. http://www.ncbi.nlm.nih.gov/pubmed/6973944?dopt=AbstractPlus
234. Wood GM, Bolton RP, Muers MF et al. Pleurisy and pulmonary granulomas after treatment with acebutolol. BMJ. 1982; 285:936. http://www.ncbi.nlm.nih.gov/pubmed/6811073?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1499959&blobtype=pdf
235. Leggett RJE. Pleurisy and pulmonary granulomas after treatment with acebutolol. BMJ. 1982; 285:1425.
236. Lyall MG, Bainbridge JG, Khambatta RB. Ophthalmological monitoring of patients receiving long-term acebutolol. Br J Clin Pharmacol. 1983; 16:574-6. http://www.ncbi.nlm.nih.gov/pubmed/6639845?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1428070&blobtype=pdf
237. Welsh N, Leary WP, Van Der Byl K. Acebutolol: prolonged administration without ophthalmological complications. Curr Ther Res. 1983; 33:611-5.
238. Martin DE, Kammerer WS. The hypertensive surgical patient: controversies in management. Surg Clin North Am. 1983; 63:1017-33. http://www.ncbi.nlm.nih.gov/pubmed/6138862?dopt=AbstractPlus
239. Dumez Y, Chobroutsky C, Hornych H et al. Neonatal effects of maternal administration of acebutolol. BMJ. 1981; 283:1077-9. http://www.ncbi.nlm.nih.gov/pubmed/6794766?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1507531&blobtype=pdf
240. Williams ER, Morrissey JR. A comparison of acebutolol with methyldopa in hypertensive pregnancy. Pharmatherapeutica. 1983; 3:487-91. http://www.ncbi.nlm.nih.gov/pubmed/6669592?dopt=AbstractPlus
241. Dubois D, Petitcolas J, Temperville B et al. Treatment of hypertension in pregnancy with β-adrenoceptor antagonists. Br J Clin Pharmacol. 1982; 13(Suppl):375-8S. http://www.ncbi.nlm.nih.gov/pubmed/7059437?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1402120&blobtype=pdf
242. Lewis M, Kallenbach J, Germond C et al. Survival following massive overdose of adrenergic blocking agents (acebutolol and labetalol). Eur Heart J. 1983; 4:328-32. http://www.ncbi.nlm.nih.gov/pubmed/6617679?dopt=AbstractPlus
243. Sangster B, de Wildt D, van Dijk A. A case of acebutolol intoxication. J Toxicol Clin Toxicol. 1983; 20:69-77. http://www.ncbi.nlm.nih.gov/pubmed/6887301?dopt=AbstractPlus
244. Zaman R, Kendall MJ. The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide. Br J Clin Pharmacol. 1982; 13:507-12. http://www.ncbi.nlm.nih.gov/pubmed/6802160?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1402050&blobtype=pdf
245. Ashton WL. An open, multicentre study of acebutolol, given as a single daily dose, in the management of hypertension. Curr Med Res Opin. 1977; 5:279-83. http://www.ncbi.nlm.nih.gov/pubmed/162667?dopt=AbstractPlus
246. Ashton WL. Acebutolol (400 mg) given as a single daily dose to hypertensive patients previously stabilized on 400 mg acebutolol daily in divided doses: an open multicentre study. Curr Med Res Opin. 1978; 5:347-53.
247. Watson RDS, Stallard TJ, Littler WA. Comparison of once and twice daily administration of acebutolol in hypertension. Br J Clin Pharmacol. 1980; 9:209-12. http://www.ncbi.nlm.nih.gov/pubmed/6766731?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1429867&blobtype=pdf
248. Frick MH, Kala R. Antiarrhythmic significance of dosing intervals in beta receptor blocking therapy of hypertension with acebutolol. Am J Cardiol. 1981; 48:911-6. http://www.ncbi.nlm.nih.gov/pubmed/6118059?dopt=AbstractPlus
249. Klug E, Schneider V. Todliche Vergiftung mit Acebutolol (Prent). (German; with English abstract.) Z Rechtsmed. 1979; 83:325-30.
250. Beyer H, Blank P, Kelch L et al. Letale Vergiftung mit Acebutolol. (German; with English abstract.) Intensivmed Prax. 1981; 18:83-5.
251. Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J. 1980; 100:160-78. http://www.ncbi.nlm.nih.gov/pubmed/6105819?dopt=AbstractPlus
252. Woods PB, Robinson ML. An investigation of the comparative liposolubilities of β-adrenoceptor blocking agents. J Pharm Pharmacol. 1981; 33:172-3. http://www.ncbi.nlm.nih.gov/pubmed/6116760?dopt=AbstractPlus
253. The United States pharmacopeia, 24th rev, and The national formulary, 19th ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 2000:15.
254. Bigger JT Jr, Hoffman BF. Antiarrhythmic drugs. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:748-83.
255. Chatterji AN. A randomized crossover comparison of acebutolol and methyldopa in the treatment of mild to moderate essential hypertension. Curr Med Res Opin. 1978; 5:675-81. http://www.ncbi.nlm.nih.gov/pubmed/367712?dopt=AbstractPlus
256. Anon. Drugs for cardiac arrhythmias. Med Lett Drugs Ther. 1986; 28:111-6. http://www.ncbi.nlm.nih.gov/pubmed/2878351?dopt=AbstractPlus
257. Gosselin RE, Smith RP, Hodge HC. Clinical toxicology of commercial products. 5th ed. Baltimore: Williams & Wilkins; 1984:I-8.
258. Frishman W, Jacob H, Eisenberg E et al. Clinical pharmacology of the new β-adrenergic blocking drugs. Part 8. Self-poisoning with beta-adrenoceptor blocking agents: recognition and management. Am Heart J. 1979; 98:798-811. http://www.ncbi.nlm.nih.gov/pubmed/40429?dopt=AbstractPlus
259. Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med. 1984; 13:1123-31. http://www.ncbi.nlm.nih.gov/pubmed/6150667?dopt=AbstractPlus
260. Anon. Beta-blocker poisoning. Lancet. 1980; 1:803-4.
261. Machin PJ, Hurst DN, Bradshaw RN et al. β-Selective adrenoceptor antagonists. Part 2: 4-ether-linked phenoxypropanolamines. J Med Chem. 1983; 26:1570-6. http://www.ncbi.nlm.nih.gov/pubmed/6138435?dopt=AbstractPlus
262. Broadhurst AD. Comparison of effect on psychomotor performance of single doses of propranolol and acebutolol. Curr Med Res Opin. 1980; 7:33-8. http://www.ncbi.nlm.nih.gov/pubmed/7428410?dopt=AbstractPlus
263. Kayed K, Godtlibsen OB. Central effects of the β-adrenergic blocking agent acebutolol: a quantitative EEG study using normalised slope descriptors. Eur J Clin Pharmacol. 1977; 12:327-31. http://www.ncbi.nlm.nih.gov/pubmed/598404?dopt=AbstractPlus
264. Kayed K, Godtlibsen OB. Effects of the β-adrenoceptor antagonists acebutolol and metoprolol on sleep pattern in normal subjects. Eur J Clin Pharmacol. 1977; 12:323-6. http://www.ncbi.nlm.nih.gov/pubmed/598403?dopt=AbstractPlus
265. Lewis MJ, Jones DM, Dart AM et al. The psychological side effects of acebutolol and atenolol. Br J Clin Pharmacol. 1984; 17:364-6. http://www.ncbi.nlm.nih.gov/pubmed/6712870?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1463380&blobtype=pdf
266. Lewis BS, Mitha AS, Gotsman MS. Acebutolol in cardiac arrhythmias. S Afr Med J. 1974; 4:821-4.
267. Booth RJ, Bullock JY, Wilson JD. Antinuclear antibodies in patients on acebutolol. Br J Clin Pharmacol. 1980; 9:515-7. http://www.ncbi.nlm.nih.gov/pubmed/6104977?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1429946&blobtype=pdf
268. Wilson FS (Wyeth Laboratories Inc, Philadelphia, PA): Personal communication; 1987.
269. Anon. Choice of a beta-blocker. Med Lett Drugs Ther. 1986; 28:20-2. http://www.ncbi.nlm.nih.gov/pubmed/2869400?dopt=AbstractPlus
270. Wallin JD, Shah SV. β-Adrenergic blocking agents in the treatment of hypertension: choices based on pharmacological properties and patient characteristics. Arch Intern Med. 1987; 147:654-9. http://www.ncbi.nlm.nih.gov/pubmed/2881524?dopt=AbstractPlus
271. McDevitt DG. β-Adrenoceptor blocking drugs and partial agonist activity: is it clinically relevant? Drugs. 1983; 25:331-8.
272. McDevitt DG. Clinical significance of cardioselectivity: state-of-the-art. Drugs. 1983; 25(Suppl 2):219-26.
273. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305:500-6. http://www.ncbi.nlm.nih.gov/pubmed/6114433?dopt=AbstractPlus
274. Thadani U, Davidson C, Chir B et al. Comparison of the immediate effects of five β-adrenoceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979; 300:750-5. http://www.ncbi.nlm.nih.gov/pubmed/581782?dopt=AbstractPlus
275. Lewis RV, McDevitt DG. Adverse reactions and interactions with β-adrenoceptor blocking drugs. Med Toxicol. 1986; 1:343-61. http://www.ncbi.nlm.nih.gov/pubmed/2878346?dopt=AbstractPlus
276. Bradberry JC. Discontinuing β blockers. Clin Pharm. 1984; 3:457,460.
277. Reviewers’ comments (personal observations); 1987.
278. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J. 1987; 113:1190-8. http://www.ncbi.nlm.nih.gov/pubmed/2883867?dopt=AbstractPlus
279. Abengowe CU, Rehan N. Acebutolol in the treatment of hypertension in African patients. Curr Ther Res. 1987; 41:737-45.
280. 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988; 148:1023-38. http://www.ncbi.nlm.nih.gov/pubmed/3365073?dopt=AbstractPlus
281. Tanner LA, Bosco LA, Zimmerman HJ. Hepatic toxicity after acebutolol therapy. Am Intern Med. 1989; 111:533-4.
282. Webster J. Interactions of NSAIDs with diuretics and β-blockers: mechanisms and clinical implications. Drugs. 1985; 30:32-41. http://www.ncbi.nlm.nih.gov/pubmed/2863124?dopt=AbstractPlus
283. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987; 107:628-35. http://www.ncbi.nlm.nih.gov/pubmed/2889416?dopt=AbstractPlus
284. Watkins J, Abbott EC, Hensby CN et al. Attenuation of hypotensive effects of propranolol and thiazide diuretics by indomethacin. Br Med J. 1980; 281:702-5. http://www.ncbi.nlm.nih.gov/pubmed/7427409?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1713997&blobtype=pdf
285. Mills EH, Whitworth JA, Andrews J et al. Non-steroidal anti-inflammatory drugs and blood pressure. Aust N Z J Med. 1982; 12:478-82. http://www.ncbi.nlm.nih.gov/pubmed/6758745?dopt=AbstractPlus
286. Durao V, Prata MM, Goncalves LMP. Modification of antihypertensive effect of β-adrenoreceptor-blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet. 1977; 2:1005-7. http://www.ncbi.nlm.nih.gov/pubmed/72901?dopt=AbstractPlus
287. Salvetti A, Arzilli F, Pedrinelli R et al. Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients. Eur J Clin Pharmacol. 1982; 22:197-201. http://www.ncbi.nlm.nih.gov/pubmed/7049707?dopt=AbstractPlus
288. Beta blockers/NSAIDs. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1989: 154.
289. Boissel JP, Lezorovicz A, Picolet H et al. Efficacy of acebutolol after acute myocardial infarction (the APSI Trial). Am J Cardiol. 1990; 66:24-31C.
290. Boissel JP, Leizorovicz A, Picolet H et al. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol. 1990; 66:251-60. http://www.ncbi.nlm.nih.gov/pubmed/2195860?dopt=AbstractPlus
291. De Backer G. Multicentre study of the efficacy and tolerance of acebutolol versus atenolol in the long term treatment of mild arterial hypertension. Drugs. 1988; 36(Suppl 2):51-6. http://www.ncbi.nlm.nih.gov/pubmed/3063506?dopt=AbstractPlus
292. Clucas A, Miller N. Effects of acebutolol on the serum lipid profile. Drugs. 1988; 36(Suppl 2):41-50. http://www.ncbi.nlm.nih.gov/pubmed/3063505?dopt=AbstractPlus
293. Reviewers’ comments (personal observations).
294. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). Circulation. 1990; 82:664-707. http://www.ncbi.nlm.nih.gov/pubmed/2197021?dopt=AbstractPlus
295. Goldman L, Sia STB, Cook EF et al. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med. 1988; 319:152-7. http://www.ncbi.nlm.nih.gov/pubmed/2898733?dopt=AbstractPlus
296. Yusuf S, Peto R, Lewis J et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985; 27:335-71. http://www.ncbi.nlm.nih.gov/pubmed/2858114?dopt=AbstractPlus
297. Pedersen TR for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med. 1985; 313:1055-8. http://www.ncbi.nlm.nih.gov/pubmed/2864634?dopt=AbstractPlus
298. Frishman WH, Furberg CD, Friedewald WT. β-Adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med. 1984; 310:830-7. http://www.ncbi.nlm.nih.gov/pubmed/6142420?dopt=AbstractPlus
299. Furberg CD. Secondary prophylaxis after acute myocardial infarction. Am J Cardiol. 1987; 60:28-32A. http://www.ncbi.nlm.nih.gov/pubmed/3604941?dopt=AbstractPlus
300. Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction. Eur Heart J. 1983; 4:367-75. http://www.ncbi.nlm.nih.gov/pubmed/6617682?dopt=AbstractPlus
301. Schroder R. Oxprenolol in myocardial infarction survivors: brief review of the European infarction study results in light of other beta-blocker postinfarction trials. Z Kardiol. 1985; 74(Suppl 6):165-72. http://www.ncbi.nlm.nih.gov/pubmed/2869616?dopt=AbstractPlus
302. European Infarction Study Group. European infarction study (E.I.S.): a secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. Eur Heart J. 1984; 5:189-202. http://www.ncbi.nlm.nih.gov/pubmed/6373264?dopt=AbstractPlus
303. Taylor SH, Silke B, Ebbutt A et al. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med. 1982; 307:1293-1301. http://www.ncbi.nlm.nih.gov/pubmed/6752712?dopt=AbstractPlus
305. Wyeth-Ayerst Laboratories, Radnor, PA: Personal communication.
307. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153:149-52. http://www.ncbi.nlm.nih.gov/pubmed/8422205?dopt=AbstractPlus
308. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: an overview of randomized drug trials in their epidemiological context. Lancet. 1990; 335:827-38. http://www.ncbi.nlm.nih.gov/pubmed/1969567?dopt=AbstractPlus
309. Alderman MH. Which antihypertensive drugs first—and why! JAMA. 1992; 267:2786-7. Editorial.
310. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335:765-74. http://www.ncbi.nlm.nih.gov/pubmed/1969518?dopt=AbstractPlus
311. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265:3255-64. http://www.ncbi.nlm.nih.gov/pubmed/2046107?dopt=AbstractPlus
312. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-hypertension). Lancet. 1991; 338:1281-5. http://www.ncbi.nlm.nih.gov/pubmed/1682683?dopt=AbstractPlus
313. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992; 304:405-12. http://www.ncbi.nlm.nih.gov/pubmed/1445513?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1995577&blobtype=pdf
314. National Heart, Lung, and Blood Institute. NHLBI panel reviews safety of calcium channel blockers. Rockville, MD; 1995 Aug 31. Press release.
315. National Heart, Lung, and Blood Institute. New analysis regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. Rockville, MD; 1995 Sep 1.
316. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274:620-5. http://www.ncbi.nlm.nih.gov/pubmed/7637142?dopt=AbstractPlus
317. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation. 1995; 92:1079-82. Editorial.
318. Roche. Posicor (mibefradil hydrochloride) tablets prescribing information. Nutley, NJ; 1997 Dec.
319. Ellison RH. Dear doctor letter regarding appropriate use of Posicor. Nutley, NJ: Roche Laboratories; 1997 Dec.
320. Sidmak Laboratories. Verapamil hydrochloride tablets prescribing information. East Hanover, NJ; 1996 Apr.
321. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)
322. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. http://www.ncbi.nlm.nih.gov/pubmed/8622249?dopt=AbstractPlus
323. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45. http://www.ncbi.nlm.nih.gov/pubmed/9042847?dopt=AbstractPlus
324. Whelton PK, Appel LJ, Espeland MA et al. for the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998; 279:839-46. http://www.ncbi.nlm.nih.gov/pubmed/9515998?dopt=AbstractPlus
326. Genuth P. United Kingdom prospective diabetes study results are in. J Fam Pract. 1998; 47:(Suppl 5):S27.
328. Watkins PJ. UKPDS: a message of hope and a need for change. Diabet Med. 1998; 15:895-6. http://www.ncbi.nlm.nih.gov/pubmed/9827842?dopt=AbstractPlus
329. Bretzel RG, Voit K, Schatz H et al. The United Kingdom Prospective Diabetes Study (UKPDS): implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1998; 106:369-72. http://www.ncbi.nlm.nih.gov/pubmed/9831300?dopt=AbstractPlus
330. Tatti P, Pahor M, Byington RP et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998; 21:597-603. http://www.ncbi.nlm.nih.gov/pubmed/9571349?dopt=AbstractPlus
331. American Diabetes Association. The United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes: what you need to know about the results of a long-term study. Washington, DC; 1998 Sep 15 from American Diabetes Association web site. http://www.diabetes.org
332. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-20. http://www.ncbi.nlm.nih.gov/pubmed/9732338?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=28660&blobtype=pdf
333. Davis TME. United Kingdom Prospective Diabetes Study: the end of the beginning? Med J Aust. 1998; 169:511-2.
335. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9A-38A.
336. Lim PO, MacDonald TM. Antianginal and β-adrenergic blocking drugs. In: Dukes MNG, ed. Meyler’s side effects of drugs. 13th ed. New York: Elsevier/North Holland Inc; 1996:488-535.
337. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000; 342:905-12. http://www.ncbi.nlm.nih.gov/pubmed/10738048?dopt=AbstractPlus
338. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000; 342:969-70. http://www.ncbi.nlm.nih.gov/pubmed/10738057?dopt=AbstractPlus
339. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. http://www.ncbi.nlm.nih.gov/pubmed/10818056?dopt=AbstractPlus
340. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. http://www.ncbi.nlm.nih.gov/pubmed/10818055?dopt=AbstractPlus
341. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. http://www.ncbi.nlm.nih.gov/pubmed/10977801?dopt=AbstractPlus
342. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-62. http://www.ncbi.nlm.nih.gov/pubmed/9635947?dopt=AbstractPlus
345. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol. 2001; 38:1266i-lxx.
347. Ryan TJ, Antman EM, Brooks NH et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Managment of Acute Myocardial Infarction). From ACC web site. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx
348. ACC/AHA guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Chronic Stable Angina). 2002. From ACC web site. Accessed 2003 Feb 13. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx
349. Williams CL, Hayman LL, Daniels SR et al. Cardiovascular health in childhood: a statement for health professional from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002; 106:143-60. http://www.ncbi.nlm.nih.gov/pubmed/12093785?dopt=AbstractPlus
350. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002. From ACC web site. Accessed Sep. 10, 2002. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx
352. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60. http://www.ncbi.nlm.nih.gov/pubmed/12479770?dopt=AbstractPlus
353. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. http://www.ncbi.nlm.nih.gov/pubmed/12479763?dopt=AbstractPlus
355. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-41.
357. The Guidelines Subcommitee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension. 1999; 17:392-403.
359. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. http://www.ncbi.nlm.nih.gov/pubmed/15811979?dopt=AbstractPlus
360. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. http://www.ncbi.nlm.nih.gov/pubmed/15811986?dopt=AbstractPlus
361. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)
501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. http://www.ncbi.nlm.nih.gov/pubmed/24352797?dopt=AbstractPlus
502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. http://www.ncbi.nlm.nih.gov/pubmed/23817082?dopt=AbstractPlus
503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85. http://www.ncbi.nlm.nih.gov/pubmed/24243703?dopt=AbstractPlus
504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26. http://www.ncbi.nlm.nih.gov/pubmed/24341872?dopt=AbstractPlus
505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503. http://www.ncbi.nlm.nih.gov/pubmed/24424788?dopt=AbstractPlus
506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4. http://www.ncbi.nlm.nih.gov/pubmed/24549531?dopt=AbstractPlus
507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6. http://www.ncbi.nlm.nih.gov/pubmed/24352710?dopt=AbstractPlus
508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8. http://www.ncbi.nlm.nih.gov/pubmed/24352759?dopt=AbstractPlus
515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88. http://www.ncbi.nlm.nih.gov/pubmed/24591473?dopt=AbstractPlus
523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.
524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.
526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :. http://www.ncbi.nlm.nih.gov/pubmed/24788967?dopt=AbstractPlus
527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3695607&blobtype=pdf
530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8. http://www.ncbi.nlm.nih.gov/pubmed/24641124?dopt=AbstractPlus
536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012: 2: 337-414.
800. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; :.
1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:el13-e115. http://www.ncbi.nlm.nih.gov/pubmed/29133356?dopt=AbstractPlus
1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med. 2018; 378:497-499. http://www.ncbi.nlm.nih.gov/pubmed/29341841?dopt=AbstractPlus
1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168:351-358. http://www.ncbi.nlm.nih.gov/pubmed/29357392?dopt=AbstractPlus
1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Press. 2018; 27:62-65. http://www.ncbi.nlm.nih.gov/pubmed/29447001?dopt=AbstractPlus
1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166:430-437. http://www.ncbi.nlm.nih.gov/pubmed/28135725?dopt=AbstractPlus
1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=AbstractPlus
1216. Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018; 378:636-644. http://www.ncbi.nlm.nih.gov/pubmed/29443671?dopt=AbstractPlus
1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA. 2017; 318:2132-2134. http://www.ncbi.nlm.nih.gov/pubmed/29159416?dopt=AbstractPlus
1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med. 2018; 178:755-7. http://www.ncbi.nlm.nih.gov/pubmed/29710197?dopt=AbstractPlus
1223. LeFevre M. ACC/AHA hypertension guideline: what is new? what do we do?. Am Fam Physician. 2018; 97(6):372-3. http://www.ncbi.nlm.nih.gov/pubmed/29671534?dopt=AbstractPlus
1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. https://www.jwatch.org/na45778/2017/12/28/nejm-journal-watch-general-medicine-year-review-2017
1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2018; 319(2):115-6. http://www.ncbi.nlm.nih.gov/pubmed/29242891?dopt=AbstractPlus
1235. Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens. 2017; 11(1):54-65. http://www.ncbi.nlm.nih.gov/pubmed/28057444?dopt=AbstractPlus
More about acebutolol
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (6)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: cardioselective beta blockers
- Breastfeeding
- En español